Therapeutic antibodies: Market considerations, disease targets and bioprocessing

International Journal of Pharmaceutics

Volumn 440, Issue 1, 2013, Pages 83-98

  Elvin, John G ^a   Couston, Ruairidh G ^b   Van Der Walle, Christopher F ^b  

^a MEDIMMUNE   (United States)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Biopharmaceutical; Bioprocessing; Immune disorder; Market; Monoclonal antibody; Oncology

Indexed keywords

ABCIXIMAB; ABLYNX; ADALIMUMAB; ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; BELIMUMAB; BEVACIZUMAB; CANAKINUMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TANDABS; THERAPEUTIC ANTIBODY; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ANTIBODY RESPONSE; ARTICLE; BIOPROCESS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; INFLAMMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNE SYSTEM DISEASES; MARKETING; NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEIN ENGINEERING;

EID: 84871622500     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2011.12.039     Document Type: Article

References (158)

1. W.S. Annan, M. Fairhead, P. Pereira, and C.F. van der Walle Emulsifying performance of modular beta-sandwich proteins: the hydrophobic moment and conformational stability Protein Eng. Des. Sel. 19 2006 537 545
2. K.L. Armour, C.S. Smith, and M.R. Clark Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding J. Immunol. Methods 354 2010 20 33
3. J.K. Atwal, Y. Chen, C. Chiu, D.L. Mortensen, W.J. Meilandt, Y. Liu, C.E. Heise, K. Hoyte, W. Luk, Y. Lu, K. Peng, P. Wu, L. Rouge, Y. Zhang, R.A. Lazarus, K. Scearce-Levie, W. Wang, Y. Wu, M. Tessier-Lavigne, and R.J. Watts A therapetuic antibody targeting BACE1 inhibits amyloid-beta production in vivo Sci. Transl. Med. 3 2011 84ra43
4. Y. Bai, C. Wu, J. Zhao, Y.H. Liu, W. Ding, and W.L. Ling Role of iron and sodium citrate in animal protein-free CHO cell culture medium on cell growth and monoclonal antibody production Biotechnol. Prog. 27 2011 209 219
5. J.S. Bee, J.L. Stevenson, B. Mehta, J. Svitel, J. Pollastrini, R. Platz, E. Freund, J.F. Carpenter, and T.W. Randolph Response of a concentrated monoclonal antibody formulation to high shear Biotechnol. Bioeng. 103 2009 936 943
6. K.M. Beeh, M. Ksoll, and R. Buhl Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals Eur. Resp. J. 16 2000 609 614
7. T.M. Behr, M. Behe, M. Lohr, G. Sgouros, C. Angerstein, E. Wehrmann, K. Nebendahl, and W. Becker Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies Eur. J. Nucl. Med. 27 2000 753 765
8. J.G. Biddlecombe, A.V. Craig, H. Zhang, S. Uddin, S. Mulot, B.C. Fish, and D.G. Bracewell Determining antibody stability: creation of solid-liquid interfacial effects within a high shear environment Biotechnol. Prog. 23 2007 1218 1222
9. J.G. Biddlecombe, G. Smith, S. Uddin, S. Mulot, D. Spencer, C. Gee, B.C. Fish, and D.G. Bracewell Factors influencing antibody stability at solid-liquid interfaces in a high shear environment Biotechnol. Prog. 25 2009 1499 1507
10. B. Bielekova, and B.L. Becker Monoclonal antibodies in MS: mechanisms of action Neurology 74 Suppl. 1 2010 S31 S40
11. BMJ2011;343:d4244. FDA committee votes to withdraw bevacizumab for breast cancer. BMJ, doi:10.1136/bmj.d4244.
12. C. Bokemeyer Catumaxomab - trifunctional anti-EpCAM antibody used to treat malignant ascites Expert Opin. Biol. Ther. 10 2010 1259 1269
13. W.K. Boland, and G. Bebb Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity Expert Opin. Biol. Ther. 9 2009 1199 1206
14. S.R. Brych, Y.R. Gokarn, H. Hultgen, R.J. Stevenson, R. Rajan, and M. Matsumura Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation J. Pharm. Sci. 99 2010 764 781
15. H.A. Burris Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer Expert Opin. Biol. Ther. 11 2011 807 819
16. M. Campiglio, R. Bufalino, M. Sandri, E. Ferri, R.A. Aiello, A. De Matteis, M. Mottolese, S. De Placido, P. Querzoli, A. Jirillo, A. Bottini, M. Fantini, A. Bonetti, F. Pedani, M. Mauri, A. Molino, A. Ferro, S.M. Pupa, M. Sasso, S. Menard, A. Balsari, and E. Tagliabue Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study Breast Cancer Res. Treat. 128 2011 147 154
17. W.P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C.P. Price Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer Clin. Chem. 49 2003 1579 1598
18. P.J. Carter Introduction to current and future protein therapeutics: a protein engineering perspective Exp. Cell Res. 317 2011 1261 1269
19. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene Blood 99 2002 754 758
20. D. Chelius, P. Ruf, P. Gruber, M. Ploscher, R. Liedtke, E. Gansberger, J. Hess, M. Wasiliu, and H. Lindhofer Structural and functional characterization of the trifunctional antibody catumaxomab MAbs 2 2010 309 319
21. V. Chen Performance of partially permeable microfiltration membranes under low fouling conditions J. Membrane Sci. 147 1998 265 278
22. V. Chen, K.J. Kim, and A.G. Fane Effect of membrane morphology and operation on protein deposition in ultrafiltration membranes Biotechnol. Bioeng. 47 1995 174 180
23. Y. Chen, C. Wiesmann, G. Fuh, B. Li, H.W. Christinger, P. McKay, A.M. de Vos, and H.B. Lowman Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen J. Mol. Biol. 293 1999 865 881
24. D.H. Choi, J.W. Suh, K.W. Park, H.J. Kang, and H.S. Kim Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: a prospective, open-label, randomized, controlled study in Korean patients Clin. Ther. 31 2009 1804 1811
25. A.J. Coles, M. Wing, S. Smith, F. Coraddu, S. Greer, C. Taylor, A. Weetman, G. Hale, V.K. Chatterjee, H. Waldmann, and A. Compston Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis Lancet 354 1999 1691 1695
26. A. Cooper, C.M. Johnson, J.H. Lakey, and M. Nollmann Heat does not come in different colours: entropy-enthalpy compensation, free energy windows, quantum confinement, pressure perturbation calorimetry, solvation and the multiple causes of heat capacity effects in biomolecular interactions Biophys. Chem. 93 2001 215 230
27. A.H. Cross, J.L. Stark, J. Lauber, M.J. Ramsbottom, and J.A. Lyons Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients J. Neuroimmunol. 180 2006 63 70
28. F. d'Amore, J. Radford, T. Relander, M. Jerkeman, H. Tilly, A. Osterborg, F. Morschhauser, M. Gramatzki, M. Dreyling, B. Bang, and H. Hagberg Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma Br. J. Haematol. 150 2010 565 573
29. J. den Engelsman, P. Garidel, R. Smulders, H. Koll, B. Smith, S. Bassarab, A. Seidl, O. Hainzl, and W. Jiskoot Strategies for the assessment of protein aggregates in pharmaceutical biotech product development Pharm. Res. 28 2011 920 933
30. R. Dienstmann, and J. Tabernero Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer Curr. Opin. Investig. Drugs 11 2010 1434 1441
31. D. Eastwood, L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, C. Burns, R. Thorpe, and R. Stebbings Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells Br. J. Pharmacol. 161 2010 512 526
32. B. Eu, A. Cairns, G. Ding, X. Cao, and Z.Q. Wen Direct visualization of protein adsorption to primary containers by gold nanoparticles J. Pharm. Sci. 100 2011 1663 1670
33. EvaluatePharma, June 17, 2009. Biotech set to dominate drug industry growth, http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id= 188700§ionID=&isEPVantage=yes; (accessed 18 July 2011).
34. M. Fairhead, K.A. Johnson, T. Kowatz, S.A. McMahon, L.G. Carter, M. Oke, H. Liu, J.H. Naismith, and C.F. van der Walle Crystal structure and silica condensing activities of silicatein alpha-cathepsin L chimeras Chem. Commun. (Camb.) 2008 1765 1767
35. R.J. Falconer, C. Chan, K. Hughes, and T.P. Munro Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients J. Chem. Technol. Biotechnol. 86 2011 942 948
36. A.A. Fasanmade, O.J. Adedokun, M. Plank, H. Zhou, and H.M. Davis Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials Clin. Ther. 33 2011 946 964
37. K.V. Foyil, and N.L. Bartlett Brentuximab vedotin for the treatment of CD30+ lymphomas Immunotherapy 3 2011 475 485
38. M.M. Freeman, M.S. Seaman, S. Rits-Volloch, X. Hong, C.Y. Kao, D.D. Ho, and B. Chen Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody Structure 18 2010 1632 1641
39. E. Gabellieri, and G.B. Strambini ANS fluorescence detects widespread perturbations of protein tertiary structure in ice Biophys. J. 90 2006 3239 3245
40. P. Gagnon IgG aggregate removal by charged-hydrophobic mixed mode chromatography Curr. Pharm. Biotechnol. 10 2009 434 439
41. P. Gagnon, and K. Beam Antibody aggregate removal by hydroxyapatite chromatography Curr. Pharm. Biotechnol. 10 2009 440 446
42. A. Ganesan, N.C. Price, S.M. Kelly, I. Petry, B.D. Moore, and P.J. Halling Circular dichroism studies of subtilisin Carlsberg immobilised on micron sized silica particles Biochim. Biophys. Acta: Proteins Proteomics 1764 2006 1119 1125
43. G. Garrido, I.A. Tikhomirov, A. Rabasa, E. Yang, E. Gracia, N. Iznaga, L.E. Fernandez, T. Crombet, R.S. Kerbel, and R. Perez Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile Cancer Biol. Ther. 11 2011 373 382
44. R.D. Gay, A.W. Clarke, Z. Elgundi, T. Domagala, R.J. Simpson, N.B. Le, A.G. Doyle, and P.A. Jennings Anti-TNFalpha domain antibody construct CEP-37247: full antibody functionality at half the size MAbs 2 2010 625 638
45. K. Gordon, K. Papp, Y. Poulin, Y. Gu, S. Rozzo, and E.H. Sasso Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL J. Am. Acad. Dermatol. 2011 10.1016/j.jaad.2010.12.005
46. M.J. Gramer, J.J. Eckblad, R. Donahue, J. Brown, C. Shultz, K. Vickerman, P. Priem, E.T.J. van den Bremer, J. Gerritsen, and P.H.C. van Berkel Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose Biotechnol. Bioeng. 108 2011 1591 1602
47. I. Gravanis, J. Ersboll, E. Skovlund, E. Abadie, M. Marty, and F. Pignatti The European medicines agency review of ofatumumab (Arzerra(R)) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use Oncologist 15 2010 1335 1343
48. R. Gray, S. Bhattacharya, C. Bowden, K. Miller, and R.L. Comis Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer J. Clin. Oncol. 27 2009 4966 4972
49. R. Hahn, R. Schlegel, and A. Jungbauer Comparison of protein A affinity sorbents J. Chromatogr. B 790 2003 35 51
50. R. Hahn, K. Shimahara, F. Steindl, and A. Jungbauer Comparison of protein A affinity sorbents III. Life time study J. Chromatogr. A 1102 2006 224 231
51. R. Hahn, P. Bauerhansl, K. Shimahara, C. Wizniewski, A. Tscheliessnig, and A. Jungbauer Comparison of protein A affinity sorbents II. Mass transfer properties J. Chromatogr. A 1093 2005 98 110
52. S. Hayavi, and G.W. Halbert Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture Biotechnol. Prog. 21 2005 1262 1268
53. S. Hermeling, D.J. Crommelin, H. Schellekens, and W. Jiskoot Structure-immunogenicity relationships of therapeutic proteins Pharm. Res. 21 2004 897 903
54. S. Hober, K. Nord, and M. Linhult Protein A chromatography for antibody purification J. Chromatogr. B 848 2007 40 47
55. E.D. Hsi, R. Steinle, B. Balasa, S. Szmania, A. Draksharapu, B.P. Shum, M. Huseni, D. Powers, A. Nanisetti, Y. Zhang, A.G. Rice, A. van Abbema, M. Wong, G. Liu, F. Zhan, M. Dillon, S. Chen, S. Rhodes, F. Fuh, N. Tsurushita, S. Kumar, V. Vexler, J.D. Shaughnessy Jr., B. Barlogie, F. van Rhee, M. Hussein, D.E. Afar, and M.B. Williams CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma Clin. Cancer Res. 14 2008 2775 2784
56. W. Hueber, D.D. Patel, T. Dryja, A.M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M.H. Gold, P. Durez, P.P. Tak, J.J. Gomez-Reino, C.S. Foster, R.Y. Kim, C.M. Samson, N.S. Falk, D.S. Chu, D. Callanan, Q.D. Nguyen, K. Rose, A. Haider, and F. Di Padova Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis Sci. Transl. Med. 2 2010 52ra72
57. D.J. Irvine, A.M. Mayes, and L.G. Griffith Nanoscale clustering of RGD peptides at surfaces using comb polymers. 1. Synthesis and characterization of comb thin films Biomacromolecules 2 2001 85 94
58. J.M. Jacobson, D.R. Kuritzkes, E. Godofsky, E. DeJesus, J.A. Larson, S.P. Weinheimer, and S.T. Lewis Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults Antimicrob. Agents Chemother. 53 2009 450 457
59. J.F.J. John Drug evaluation: tefibazumab - a monoclonal antibody against staphylococcal infection Curr. Opin. Mol. Ther. 8 2006 455 460
60. F. Jourdan, L. Cottret, L. Huc, D. Wildridge, R. Scheltema, A. Hillenweck, M.P. Barrett, D. Zalko, D.G. Watson, and L. Debrauwer Use of reconstituted metabolic networks to assist in metabolomic data visualization and mining Metabolomics 6 2010 312 321
61. M.S. Kaminski, A.D. Zelenetz, O.W. Press, M. Saleh, J. Leonard, L. Fehrenbacher, T.A. Lister, R.J. Stagg, G.F. Tidmarsh, S. Kroll, R.L. Wahl, S.J. Knox, and J.M. Vose Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J. Clin. Oncol. 19 2001 3918 3928
62. G.M. Keating Rituximab A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma Drugs 70 2010 1445 1476
63. G.A. Kerchner, and A.L. Boxer Bapineuzumab Expert Opin. Biol. Ther. 10 2010 1121 1130
64. B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus, R. Hilbrands, E. Vandemeulebroucke, U. Van de Velde, L. Crenier, C. De Block, S. Candon, H. Waldmann, A.G. Ziegler, L. Chatenoud, and D. Pipeleers Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 53 2010 614 623
65. S.H.G. Khoo, F. Falciani, and M. Al-Rubeait A genome-wide transcriptional analysis of producer and non-producer NS0 myeloma cell lines Biotechnol. Appl. Biochem. 47 2007 85 95
66. K.J. Kim, V. Chen, and A.G. Fane Some factors determining protein aggregation during ultrafiltration Biotechnol. Bioeng. 42 1993 260 265
67. A.O. Kirdar, K.D. Green, and A.S. Rathore Application of multivariate data analysis for identification and successful resolution of a root cause for a bioprocessing application Biotechnol. Prog. 24 2008 720 726
68. C. Knevelman, J. Davies, L. Allen, and N.J. Titchener-Hooker High-throughput screening techniques for rapid PEG-based precipitation of IgG(4) mAb from clarified cell culture supernatant Biotechnol. Prog. 26 2010 697 705
69. J. Ko Abagovomab does not prolong progression-free survival in advanced ovarian cancer Monthly Prescribing Reference 2011
70. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
71. J.A. Konner, K.M. Bell-McGuinn, P. Sabbatini, M.L. Hensley, W.P. Tew, N. Pandit-Taskar, N. Vander Els, M.D. Phillips, C. Schweizer, S.C. Weil, S.M. Larson, and L.J. Old Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study Clin. Cancer Res. 16 2010 5288 5295
72. M. Kreiner, Z. Li, J. Beattie, S.M. Kelly, H.J. Mardon, and C.F. van der Walle Self-assembling multimeric integrin alpha5beta1 ligands for cell attachment and spreading Protein Eng. Des. Sel. 21 2008 553 560
73. M. Kreiner, C.R. Chillakuri, P. Pereira, M. Fairhead, Z. Li, H.J. Mardon, S.A. Holt, and C.F. van der Walle Orientation and surface coverage of adsorbed fibronectin cell binding domains and bound integrin α5β1 receptors Soft Matter 5 2009 3954 3962
74. Y. Krupitskaya, and H.A. Wakelee Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer Curr. Opin. Investig. Drugs 10 2009 597 605
75. B. Kuenen, P.O. Witteveen, R. Ruijter, G. Giaccone, A. Dontabhaktuni, F. Fox, T. Katz, H. Youssoufian, J. Zhu, E.K. Rowinsky, and E.E. Voest A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies Clin. Cancer Res. 16 2010 1915 1923
76. M. Kurzeja, L. Rudnicka, and M. Olszewska New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab Am. J. Clin. Dermatol. 12 2011 113 125
77. S. Lawton, G. Steele, P. Shering, L.H. Zhao, I. Laird, and X.W. Ni Continuous crystallization of pharmaceuticals using a continuous oscillatory baffled crystallizer Org. Process Res. Dev. 13 2009 1357 1363
78. A.L.Z. Lee, Y. Wang, H.Y. Cheng, S. Pervaiz, and Y.Y. Yang The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles Biomaterials 30 2009 919 927
79. R. Legmann, H.B. Schreyer, R.G. Combs, E.L. McCormick, A.P. Russo, and S.T. Rodgers A predictive high-throughput scale-down model of monoclonal antibody production in CHO cells Biotechnol. Bioeng. 104 2009 1107 1120
80. Z. Li, M. Kreiner, C.F. van der Walle, and H.J. Mardon Clustered integrin alpha5beta1 ligand displays model fibronectin-mediated adhesion of human endometrial stromal cells Biochem. Biophys. Res. Commun. 407 2011 777 782
81. Y. Lim, N.S.C. Wong, Y.Y. Lee, S.C.Y. Ku, D.C.F. Wong, and M.G.S. Yap Engineering mammalian cells in bioprocessing - current achievements and future perspectives Biotechnol. Appl. Biochem. 55 2010 175 189
82. D. Low, R. O'Leary, and N.S. Pujar Future of antibody purification J. Chromatogr. B 848 2007 48 63
83. D. Lu, X. Jimenez, H. Zhang, P. Bohlen, L. Witte, and Z. Zhu Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy Int. J. Cancer 97 2002 393 399
84. Q. Lu, J.J. Rouby, P.F. Laterre, P. Eggimann, A. Dugard, E.J. Giamarellos-Bourboulis, E. Mercier, J. Garbino, C.E. Luyt, J. Chastre, V. Georgescu-Kyburz, M.P. Rudolf, V. Gafner, H. Lazar, H. Koch, A. Perez, S.D. Kramer, and M. Tamm Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia J. Antimicrob. Chemother. 66 2011 1110 1116
85. H.C. Mahler, M. Printz, R. Kopf, R. Schuller, and R. Muller Behaviour of polysorbate 20 during dialysis, concentration and filtration using membrane separation techniques J. Pharm. Sci. 97 2008 764 774
86. T.E. Markatseli, E.S. Kaltsonoudis, P.V. Voulgari, A. Zioga, and A.A. Drosos Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab Clin. Exp. Rheumatol. 27 2009 996 998
87. S. Mazumdar Raxibacumab MAbs 1 2009 531 538
88. I.N. Micallef, M.J. Maurer, G.A. Wiseman, D.A. Nikcevich, P.J. Kurtin, M.W. Cannon, D.G. Perez, G.S. Soori, B.K. Link, T.M. Habermann, and T.E. Witzig Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Blood 2011 (Epub ahead of print)
89. T.S. Migone, G.M. Subramanian, J. Zhong, L.M. Healey, A. Corey, M. Devalaraja, L. Lo, S. Ullrich, J. Zimmerman, A. Chen, M. Lewis, G. Meister, K. Gillum, D. Sanford, J. Mott, and S.D. Bolmer Raxibacumab for the treatment of inhalational anthrax N. Engl. J. Med. 361 2009 135 144
90. K. Miller, M.L. Wang, J. Gralow, M. Dickler, M. Cobleigh, E.A. Perez, T. Shenkier, D. Cella, and N.E. Davidson Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N. Engl. J. Med. 357 2007 2666 2676
91. M. Molimard, R. Buhl, R. Niven, V. Le Gros, A. Thielen, J. Thirlwell, R. Maykut, and G. Peachey Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data Respir. Med. 104 2010 1381 1385
92. M.A. Molina, J. Codony-Servat, J. Albanell, F. Rojo, J. Arribas, and J. Baselga Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells Cancer Res. 61 2001 4744 4749
93. B.D. Moore, J. Deere, R. Edrada-Ebel, A. Ingram, and C.F. van der Walle Isolation of recombinant proteins from culture broth by co-precipitation with an amino acid carrier to form stable dry powders Biotechnol. Bioeng. 106 2010 764 773
94. S. Muyldermans, T.N. Baral, V.C. Retamozzo, P. De Baetselier, E. De Genst, J. Kinne, H. Leonhardt, S. Magez, V.K. Nguyen, H. Revets, U. Rothbauer, B. Stijlemans, S. Tillib, U. Wernery, L. Wyns, G. Hassanzadeh-Ghassabeh, and D. Saerens Camelid immunoglobulins and nanobody technology Vet. Immunol. Immunopathol. 128 2009 178 183
95. A.L. Nelson, and J.M. Reichert Development trends for therapeutic antibody fragments Nat. Biotechnol. 27 2009 331 337
96. S.P. Ng, R.W. Rounsevell, A. Steward, C.D. Geierhaas, P.M. Williams, E. Paci, and J. Clarke Mechanical unfolding of TNfn3: the unfolding pathway of a fnIII domain probed by protein engineering, AFM and MD simulation J. Mol. Biol. 350 2005 776 789
97. G. Niederfellner, A. Lammens, O. Mundigl, G.J. Georges, W. Schaefer, M. Schwaiger, A. Franke, K. Wiechmann, S. Jenewein, J.W. Slootstra, P. Timmerman, A. Brannstrom, F. Lindstrom, E. Mossner, P. Umana, K.P. Hopfner, and C. Klein Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies Blood 118 2011 358 367
98. J.M. Pagel, N. Orgun, D.K. Hamlin, D.S. Wilbur, T.A. Gooley, A.K. Gopal, S.I. Park, D.J. Green, Y. Lin, and O.W. Press A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations Blood 113 2009 4903 4913
99. F. Panza, V. Frisardi, B.P. Imbimbo, D. Seripa, V. Solfrizzi, and A. Pilotto Monoclonal antibodies against beta-amyloid (Abeta) for the treatment of Alzheimer's disease: the Abeta target at a crossroads Expert Opin. Biol. Ther. 11 2011 679 686
100. P. Pereira, S.M. Kelly, P.R. Gellert, and C.F. van der Walle Interdomain mobility and conformational stability of type III fibronectin domain pairs control surface adsorption, desorption and unfolding Colloid Surf. B: Biointerfaces 64 2008 1 9
101. P. Pereira, S.M. Kelly, A. Cooper, H.J. Mardon, P.R. Gellert, and C.F. van der Walle Solution formulation and lyophilisation of a recombinant fibronectin fragment Eur. J. Pharm. Biopharm. 67 2007 309 319
102. T.K. Pham, and P.C. Wright The proteomic response of Saccharomyces cerevisiae in very high glucose conditions with amino acid supplementation J. Proteome Res. 7 2008 4766 4774
103. L. Pickering Opportunities for Monoclonal Antibodies: Where Companies are Spending Their Antibody Dollars 2011 Decision Resources Burlington
104. A.J. Porter, A.J. Dickson, and A.J. Racher Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: realizing the potential in bioreactors Biotechnol. Prog. 26 2010 1446 1454
105. D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. van Hogezand, D.K. Podolsky, B.E. Sands, T. Braakman, K.L. DeWoody, T.F. Schaible, and S.J.H. van Deventer Infliximab for the treatment of fistulas in patients with Crohn's disease N. Engl. J. Med. 340 1999 1398 1405
106. N. Rathore, and R.S. Rajan Current perspectives on stability of protein drug products during formulation, fill and finish operations Biotechnol. Prog. 24 2008 504 514
107. B. Rehm, T. Thompson, and M. Plassmeyer Bioengineered protein A polymer beads for high-affinity antibody purification Biopharm. Int. 24 2011 36 42
108. J.M. Reichert Antibody-based therapeutics to watch in 2011 MAbs 3 2011 76 99
109. C.Q. Reid, A. Tait, H. Baldascini, A. Mohindra, A. Racher, S. Bilsborough, C.M. Smales, and M. Hoare Rapid whole monoclonal antibody analysis by mass spectrometry: an ultra scale-down study of the effect of harvesting by centrifugation on the post-translational modification profile Biotechnol. Bioeng. 107 2010 85 95
110. D.A. Rider, C.E. Havenith, R. de Ridder, J. Schuurman, C. Favre, J.C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J.G. vandeWinkel, J. Cambier, P.W. Parren, and D.R. Alexander A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity Cancer Res. 67 2007 9945 9953
111. M.K. Robinson, R.K. Alpaugh, and H. Borghaei Naptumomab estafenatox: a new immunoconjugate Expert Opin. Biol. Ther. 10 2010 273 279
112. S.S. Rogers, C. van der Walle, and T.A. Waigh Microrheology of bacterial biofilms in vitro: Staphylococcus aureus and Pseudomonas aeruginosa Langmuir 24 2008 13549 13555
113. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, M. Raskind, M. Sabbagh, L.S. Honig, R. Doody, C.H. van Dyck, R. Mulnard, J. Barakos, K.M. Gregg, E. Liu, I. Lieberburg, D. Schenk, R. Black, and M. Grundman A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
114. M. Scarff, S.A. Arnold, L.M. Harvey, and B. McNeil Near infrared spectroscopy for bioprocess monitoring and control: current status and future trends Crit. Rev. Biotechnol. 26 2006 17 39
115. C.P. Schneider, D. Shukla, and B.L. Trout Arginine and the hofmeister series: the role of ion-ion interactions in protein aggregation suppression J. Phys. Chem. B 115 2011 7447 7458
116. C. Schumann, C. Kropf, T. Wibmer, S. Rüdiger, K.M. Stoiber, A. Thielen, W. Rottbauer, and C. Kroegel Omalizumab in patients with severe asthma: The XCLUSIVE study Clin. Respir. J. 2011 10.1111/j.1752-699X.2011.00263.x
117. C.A. Sellick, D. Knight, A.S. Croxford, A.R. Maqsood, G.M. Stephens, R. Goodacre, and A.J. Dickson Evaluation of extraction processes for intracellular metabolite profiling of mammalian cells: matching extraction approaches to cell type and metabolite targets Metabolomics 6 2010 427 438
118. S. Seshadri, K.A. Oberg, and V.N. Uversky Mechanisms and consequences of protein aggregation: the role of folding intermediates Curr. Protein Pept. Sci. 10 2009 456 463
119. G. Seth, P. Hossler, J.C. Yee, and W.S. Hu Engineering cells for cell culture bioprocessing - physiological fundamentals Adv. Biochem. Eng. Biotechnol. 101 2006 119 164
120. T. Shih, and C. Lindley Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin. Ther. 28 2006 1779 1802
121. M.A.A. Siddiqui, and L.J. Scott Infliximab - a review of its use in Crohn's disease and rheumatoid arthritis Drugs 65 2005 2179 2208
122. M. Siebels, K. Rohrmann, R. Oberneder, M. Stahler, N. Haseke, J. Beck, R. Hofmann, M. Kindler, P. Kloepfer, and C. Stief A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients World J. Urol. 29 2011 121 126
123. E.R. Siemers, S. Friedrich, R.A. Dean, C.R. Gonzales, M.R. Farlow, S.M. Paul, and R.B. Demattos Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease Clin. Neuropharmacol. 33 2010 67 73
124. D.A. Smith, E.A. Minthorn, and M. Beerahee Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody Clin. Pharmacokinet. 50 2011 215 227
125. D. Soler, T. Chapman, L.L. Yang, T. Wyant, R. Egan, and E.R. Fedyk The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases J. Pharmacol. Exp. Ther. 330 2009 864 875
126. J.L. Spratlin, R.B. Cohen, M. Eadens, L. Gore, D.R. Camidge, S. Diab, S. Leong, C. O'Bryant, L.Q. Chow, N.J. Serkova, N.J. Meropol, N.L. Lewis, E.G. Chiorean, F. Fox, H. Youssoufian, E.K. Rowinsky, and S.G. Eckhardt Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J. Clin. Oncol. 28 2010 780 787
127. A. Stein Decreasing variability in your cell culture Biotechniques 43 2007 228 229
128. A.V. Stepanov, A.A. Belogurov Jr., N.A. Ponomarenko, O.A. Stremovskiy, L.V. Kozlov, A.M. Bichucher, S.E. Dmitriev, I.V. Smirnov, O.G. Shamborant, D.S. Balabashin, L.P. Sashchenko, A.G. Tonevitsky, A. Friboulet, A.G. Gabibov, and S.M. Deyev Design of targeted B cell killing agents PLoS One 6 2011 e20991
129. B.E. Strober, J.J. Crowley, P.S. Yamauchi, M. Olds, and D.A. Williams Efficacy and safety results from a phase III, randomised controlled trial comparing the safety and efficacy of briakinumab to etanercept and placebo in patients with moderate to severe chronic plaque psoriasis Br. J. Dermatol. 2011 10.1111/j. 1365-2133.2011.10419.x (Epub)
130. W.R. Strohl Therapeutic monoclonal antibodies: past, present, and future Z. An, Therapeutic Monoclonal Antibodies From Bench to Clinic 2009 John Wiley & Sons New Jersey 23 32
131. D. Strumberg, B. Schultheis, M.E. Scheulen, R.A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler, and K. Mross Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer Invest. New Drugs 2010 10.1007/s10637-010-9619-8 (Epub)
132. J. Sunyer, J.M. Anto, J. Castellsague, J.B. Soriano, J. Roca, J. MartinezMoratalla, E. Almar, M. Arevalo, A. Mateos, A. Sanchez, M. Vizcaya, F. Burgos, M.B. Galobardes, A. Tobias, N. Muniozguren, M. Errazola, A. Capelastegui, J. Ramos, J.A. Maldonado, J.L. Sanchez, A. Pereira, J. Gravalos, R. Quiros, J. Azofra, L. Palenciano, F. Payo, G. Rego, and A. Vega Total serum IgE is associated with asthma independently of specific IgE levels Eur. Respir. J. 9 1996 1880 1884
133. K. Swinnen, A. Krul, I. Van Goidsenhoven, N. Van Tichelt, A. Roosen, and K. Van Houdt Performance comparison of protein A affinity resins for the purification of monoclonal antibodies J. Chromatogr. B 848 2007 97 107
134. M. Thery, A. Jimenez-Dalmaroni, V. Racine, M. Bornens, and F. Julicher Experimental and theoretical study of mitotic spindle orientation Nature 447 2007 493 496
135. R. Thirumangalathu, S. Krishnan, M.S. Ricci, D.N. Brems, T.W. Randolph, and J.F. Carpenter Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution J. Pharm. Sci. 98 2009 3167 3181
136. H. Tilg, and A. Kaser Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease Curr. Opin. Investig. Drugs 11 2010 1295 1304
137. A.W. Tolcher, J. Sarantopoulos, A. Patnaik, K. Papadopoulos, C.C. Lin, J. Rodon, B. Murphy, B. Roth, I. McCaffery, K.S. Gorski, B. Kaiser, M. Zhu, H. Deng, G. Friberg, and I. Puzanov Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 J. Clin. Oncol. 27 2009 5800 5807
138. J. Toma, S.P. Weinheimer, E. Stawiski, J.M. Whitcomb, S.T. Lewis, C.J. Petropoulos, and W. Huang Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab J. Virol. 85 2011 3872 3880
139. M.S. Topp, P. Kufer, N. Gokbuget, M. Goebeler, M. Klinger, S. Neumann, H.A. Horst, T. Raff, A. Viardot, M. Schmid, M. Stelljes, M. Schaich, E. Degenhard, R. Kohne-Volland, M. Bruggemann, O. Ottmann, H. Pfeifer, T. Burmeister, D. Nagorsen, M. Schmidt, R. Lutterbuese, C. Reinhardt, P.A. Baeuerle, M. Kneba, H. Einsele, G. Riethmuller, D. Hoelzer, G. Zugmaier, and R.C. Bargou Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J. Clin. Oncol. 29 2011 2493 2498
140. M. Toueille, A. Uzel, J.F. Depoisier, and R. Gantier Designing new monoclonal antibody purification processes using mixed-mode chromatography sorbents J. Chromatogr. B 879 2011 836 843
141. P. Traczewski, and L. Rudnicka Treatment of systemic lupus erythematosus with epratuzumab Br. J. Clin. Pharmacol. 71 2011 175 182
142. G.D. Tredwell, B. Edwards-Jones, D.J. Leak, and J.G. Bundy The development of metabolomic sampling procedures for Pichia pastoris, and baseline metabolome data PLoS One 6 2011 e16286
143. A.K. Tyagi, T.W. Randolph, A. Dong, K.M. Maloney, C. Hitscherich Jr., and J.F. Carpenter IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles J. Pharm. Sci. 98 2009 94 104
144. I. Uettwiller, D. Dubut, and N. Voute Quantification of protein adsorption onto the surface of single-use flexible containers Bioprocess Int. 4 2006 S22 S26
145. R. van Reis, and A. Zydney Bioprocess membrane technology J. Membrane Sci. 297 2007 16 50
146. J. Varani, D.R. Inman, S.E.G. Fligiel, and W.J. Hillegas Use of recombinant and synthetic peptides as attachment factors for cells on microcarriers Cytotechnology 13 1993 89 98
147. M. Vazquez-Rey, and D.A. Lang Aggregates in monoclonal antibody manufacturing processes Biotechnol. Bioeng. 108 2011 1494 1508
148. F.M. Veronese, and G. Pasut PEGylation: posttranslational bioengineering of protein biotherapeutics Drug Discov. Today: Technol. 5 2008 e57 e64
149. T.A. Waigh Microrheology of complex fluids Rep. Prog. Phys. 68 2005 685 742
150. G.M. Walsh Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions Curr. Opin. Mol. Ther. 11 2009 329 336
151. W. Wang, S. Singh, D.L. Zeng, K. King, and S. Nema Antibody structure, instability, and formulation J. Pharm. Sci. 96 2007 1 26
152. N. Watson, G. Duncan, W.S. Annan, and C.F. van der Walle A tetravalent RGD ligand for integrin-mediated cell adhesion J. Pharm. Pharmacol. 58 2006 959 966
153. L.E. Weisman, G.W. Fischer, H.M. Thackray, K.E. Johnson, R.F. Schuman, G.T. Mandy, B.E. Stratton, K.M. Adams, W.G. Kramer, and J.J. Mond Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults Int. Immunopharmacol. 9 2009 639 644
154. WHO, 24/06/2009. General policies for monoclonal antibodies. INN Working Document 09.251.
155. A. Wiens, C.J. Correr, R. Venson, M.F. Otuki, and R. Pontarolo A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis Rheumatol. Int. 30 2010 1063 1070
156. Y. Yamashita-Kashima, S. Iijima, K. Yorozu, K. Furugaki, M. Kurasawa, M. Ohta, and F.O. Kaori Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models Clin. Cancer Res. 2011 10.1158/1078-0432.CCR-10-2927 (Epub)
157. Y.J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, J. Atwal, J.M. Elliot, S. Prabhu, R.J. Watts, and M.S. Dennis Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 3 2011 84ra44
158. J. Zhao, Y.F. Fu, M. Yasvoina, P.Z. Shao, B. Hitt, T. O'Connor, S. Logan, E. Maus, M. Citron, R. Berry, L. Binder, and R. Vassar beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: Implications for Alzheimer's disease pathogenesis J. Neurosci. 27 2007 3639 3649